How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
Karyopharm Therapeutics is under fresh scrutiny as analysts reaffirm a $28 price target while keeping the central fair value estimate steady at $15.33. That target is being framed largely around confidence in selinexor, the Phase 1 myelofibrosis data, and the projected US$800m to US$850m frontline opportunity, with bulls and bears divided on how much weight to assign to early stage results and asset concentration. Read on to see how to interpret these moving pieces and follow the evolving story around Karyopharm Therapeutics. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Karyopharm Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Rodman & Renshaw has initiated coverage with a Buy rating and a US$28 price target, anchoring its view on selinexor and the current fair value estimate of US$15.33 that some investors use as a reference point. The firm highlights selinexor's differentiated mec
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics (KPTI) was upgraded by Rodman & Renshaw to "strong-buy".MarketBeat
- Karyopharm Therapeutics (KPTI) is now covered by Rodman & Renshaw. They set a "buy" rating on the stock.MarketBeat
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 2/12/26 - Miss
KPTI
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- KPTI's page on the SEC website